...
首页> 外文期刊>Oncoimmunology. >The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation
【24h】

The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation

机译:肠道净化预防性抗生素对同种异体造血干细胞移植后急性移植物与宿主病和存活的影响

获取原文
获取原文并翻译 | 示例

摘要

The intestinal microbiota plays a key role in the pathogenesis of acute graft-versus-host disease (aGVHD). High-dose conditioning regimens given prior to allogeneic hematopoietic stem cell transplantation (aHSCT) modulate the composition of gut microbiota and damage the gut epithelial barrier, resulting in increased systemic inflammation. We assessed whether gut decontamination with antibiotics (ATB) prior to aHSCT influenced the frequency of aGVHD and mortality in 500 patients from two Canadian centers between 2005 and 2012. The rate of grade II-IV aGVHD was higher in the ATB arm compared with the arm without ATB (42% vs 28%; p < 0.001). This difference was mainly driven by a 2-fold higher rate of grade II-IV gastrointestinal aGVHD (GI-GVHD) in the ATB arm compared with the arm without ATB (20.7% vs 10.8%; p D 0.003). Multivariate analyses adjusted for known aGVHD risk factors revealed that more patients in the ATB group developed clinically significant GI-GVHD and liver aGVHD; adjusted odds ratio (aOR) D 1.83; p D 0.023 and aOR D 3.56; p D 0.047, respectively. Importantly, median overall survival (OS) was significantly lower in the group receiving ATB and the OS at 10 y remained decreased in the ATB group; adjusted hazard ratio (aHR) D 1.61 (p < 0.001).
机译:肠道微生物群在急性移植物与宿主疾病(AGVHD)的发病机制中起着关键作用。在同种异体造血干细胞移植(AHSCT)之前给出的高剂量调理方案(AHSCT)调节肠道微生物的组成并损伤肠上皮屏障,导致系统性炎症增加。我们评估了在AHSCT之前用抗生素(ATB)的肠道净化是否影响了2005年至2012年的两名加拿大中心500名患者的AGVHD和死亡率的频率。与手臂相比,II-IV AGVHD级别较高。没有ATB(42%vs 28%; P <0.001)。与没有ATB的臂相比,这种差异主要由ATB臂中的II-IV级胃肠道AGVHD(GI-GVHD)的级别增加2倍以下(20.7%Vs 10.8%; P D 0.003)。调整已知AGVHD危险因素的多变量分析显示,ATB组更多的患者在临床上显着的GI-GVHD和肝脏AGVHD。调整的赔率比(AOR)D 1.83; P D 0.023和AOR D 3.56; P d 0.047,分别。重要的是,在接受ATB的组中,中位数总存活(OS)显着降低,在ATB组中10 y的OS保持下降;调整后的危险比(AHR)D 1.61(P <0.001)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号